Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Now, Eli Lilly, the largest pharmaceutical company in the world in terms of market capitalisation, has launched its own ...

Mounjaro, a weight loss drug launched by Eli Lilly in India, could be a game-changer and has been making waves lately. Here's ...

Eli Lilly launches Mounjaro in India, targeting the $150B weight-loss market. The GLP-1 drug offers diabetes control & major ...

Eli Lilly is exploring partnerships with Indian pharma firms to market its anti-diabetes and weight loss drug Mounjaro, ...

GLP-1 receptor agonists, originally introduced in 2006, have undergone significant advancements over the years. David Ricks, ...

Mounjaro is a very big opportunity, given that a significant number of people have diabetes in India, says the CEO ...

Eli Lilly's CEO, David Ricks, reveals potential plans to manufacture the weight-loss drug Mounjaro in India as part of their global expansion.

Recently, the weight loss drug introduced by Eli Lilly, Mounjaro, has been launched in India sparking a debate among health experts ...

Unlike the US, Europe or other developed markets, Mounjaro will have to be purchased out-of-pocket in India, as obesity is ...